Plain-English translation of NCT07018622 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether dapagliflozin, a medication originally used for diabetes, can protect your kidneys from damage caused by platinum-based chemotherapy drugs like cisplatin or carboplatin. Researchers will compare people who receive the medication to those who receive a placebo (a dummy pill with no active ingredient) to see if the treatment reduces kidney injury markers in urine samples.
Platinum-based chemotherapy drugs are very effective at treating cancer, but they can damage the kidneys—sometimes causing acute kidney injury or long-term kidney disease. Current kidney protection methods (like giving extra fluids and supplements) help somewhat, but doctors are looking for better ways to specifically protect the kidney cells that are most vulnerable to this type of damage.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either dapagliflozin or a placebo to take by mouth while you undergo your platinum-based chemotherapy. Neither you nor the research team will know which group you are in until the study ends (this is called a 'blinded' study). The study will involve urine and blood samples collected at specific timepoints, especially around the time of your chemotherapy infusions, to measure kidney injury markers and assess how well the medication protects your kidneys.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Mexico